eGenesis’s goal is to transform the field of transplantation by offering safe and effective organs, tissues, and cells to patients in need. The company harnesses cutting-edge gene-editing technologies to address the key issues that have impeded xenotransplantation to date. eGenesis’s development pipeline includes lead programs for kidney and islet cell transplant as well as earlier-stage programs focused on other solid organs. The Cambridge, MA-based biotech startup co-founded by Luhan Yang, Ph.D. ’13, and George Church, the Robert Winthrop Professor of Genetics at Harvard Medical School and a core faculty member of Harvard’s Wyss Institute for Biologically Inspired Engineering.